Top of this page
Skip navigation, go straight to the content

Investors Overview

we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 

2018 integrated report

image description

2019 HY results

image description

Outlook 2019 updated

The 2019 outlook was updated on 10 January 2020. Click here to access the press release.

The acquisition of Ra Pharma will not impact UCB’s 2019 financial guidance. The acquisition would be dilutive to UCB’s mid-term earnings level due to additional planned R&D investments. As a result, the mid-term target of UCB reaching a REBITDA ratio (to revenue) of 31% would move to 2022 from 2021 as previously guided.

2019 revenue is expected to reach

approx. € 4.9 billion 

previously € 4.6-4.7 billion 

Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] 

at least at the upper end of the 27% - 29% range

previously in the range of 27-29% of revenue 

Core earnings per share will be

> € 4.80

previously in the range of € 4.40 -
€ 4.80, based on an average of 188 million shares outstanding


Contact UCB IR team or a specific team member:




UCB IR app available on Apple Store

UCB IR app available on Google Play